1. Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): A multcentre, randomized, controlled phase 3 trial. Lancet. 2018; 390: 2779-2789. doi: 10.1016/S0140-6736(17)32641-7
2. Ungaro R, Colombel JF, Lissoos T, et al. A treat-to-target update in ulcerative colitis: A systematic review. Amer J Gastro. 2019; 114: 874-883. doi: 10.14309/ajg.0000000000000183
3. Baseball-Reference. MLB stats, scores, history, and records, 2019. Web site. https://www.baseball-reference.com/. Accessed October 31, 2019.
4. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013; 369: 711-721. doi: 10.1056/NEJMoa1215739
5. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: The ACCENT I randomized trial. Lancet. 2002; 359: 1541-1549. doi: 10.1016/S0140-6736(02)08512-4
6. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease. Gastroenterology. 2007; 132(1): 52-65. doi: 10.1053/j.gastro.2006.11.041
7. Vasudevan A, Gibson PR, vanLangenberg DR. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told. World J Gastroenterol. 2017: 23(35): 6385-6402. doi: 10.3748/wjg.v23.i35.6385
8. Sandborn WJ, Rutgeerts P, Gasink C, et al. Long-term efficacy and safety of ustekinumab for Crohn’s disease through the second year of therapy. Aliment Pharmacol Ther. 2018: 48(1): 65-77. doi: 10.1111/apt.14794
9. Murthy SK, Begum J, Benchimol EL, et al. Introduction of anti-TNF therapy has not yielded expected declines in hospitalization and intestinal resection rates in inflammatory bowel diseases: A population-based interrupted time series study. Gut. 2019; pii: gutjnl-2019-318440. doi: 10.1136/gutjnl-2019-318440